Select Language

uPAR

uPAR Overview

English Name	Urokinase plasminogen activator surface receptor	Approved Drugs	0
Drugs in Clinical Trials	7	Target Synonym	Monocyte activation antigen Mo3，U-PAR，uPAR，CD87，Urokinase-Type Plasminogen Activator (UPA) Receptor，URKR，U-Plasminogen Activator Receptor Form 2，CD87 Antigen，Plasminogen Activator， Urokinase Receptor，MO3
Highest Development Stage	Phase 3 Clinical

English Name	Urokinase plasminogen activator surface receptor
Target Synonym	Monocyte activation antigen Mo3，U-PAR，uPAR，CD87，Urokinase-Type Plasminogen Activator (UPA) Receptor，URKR，U-Plasminogen Activator Receptor Form 2，CD87 Antigen，Plasminogen Activator， Urokinase Receptor，MO3
Approved Drugs	0
Drugs in Clinical Trials	7
Highest Development Stage	Phase 3 Clinical

uPAR Product List

Product Category
Protein (17)Cell (2)Beads (1)
Product Status
Launched (20)
Species
Human (12)Mouse (5)Cynomolgus (1)Rat (2)
Tag
His Tag (9)His Tag & Avi Tag (5)Fc Tag (3)- (3)
Conjugate
Unconjugated (9)Biotin-labeled (5)FITC Labeled (1)PE Labeled (1)APC Labeled (1)- (3)

Cat. No.	Species	Host	Product Description
HOT UPR-H5254	Human	HEK293	Human uPAR / PLAUR Protein, Fc Tag (MALS verified)
HOT UPR-H52H6	Human	HEK293	Human uPAR / PLAUR (209-303) Protein, His Tag (MALS verified)
HOT UPR-H82E7	Human	HEK293	Biotinylated Human uPAR / PLAUR Protein, His,Avitag™ (MALS verified)
HOT UPR-HP2H7	Human	HEK293	PE-Labeled Human uPAR / PLAUR Protein, His Tag (Site-specific conjugation)
CHEK-ATP151	Human	HEK293	HEK293/Human uPAR Stable Cell Line
MBC-K205	Human	-	Human uPAR coupled magnetic beads (2 µm)
SCCHO-ATP152	Human	CHO	CHO/Human uPAR Stable Cell Line
UPR-H5226	Human	HEK293	Human uPAR / PLAUR Protein, His Tag (MALS verified)
UPR-H52H7	Human	HEK293	Human uPAR / PLAUR (115-305) Protein, His Tag (MALS verified)
UPR-H52H8	Human	HEK293	Human uPAR / PLAUR (23-114) Protein, His Tag (HPLC verified)

Total: 20

uPAR Background

Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.

uPAR Synonyms

uPAR,PLAUR,CD87,MO3

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Gallium-68 NOTA AE105	CS-001; 68Ga-NOTA-AE105	Phase 3 Clinical	Curasight Aps, Rigshospitalet	Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Glioblastoma; Hair Diseases; Head and Neck Neoplasms; Mesothelioma; Mouth Neoplasms; Neoplasms; Neuroendocrine Tumors; Oropharyngeal Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms	Details
WAL0921	WAL0921; WAL-0921; WAL 0921	Phase 2 Clinical	Walden Biosciences Inc	Diabetic Nephropathies; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Kidney Diseases; Nephrosis, Lipoid; Renal Insufficiency, Chronic	Details
64Cu-DOTA-AE105	64Cu-DOTA-AE105	Phase 2 Clinical	Rigshospitalet	Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms	Details
FG-001	FG001; FG-001	Phase 2 Clinical	FluoGuide AS	Brain Neoplasms; Glioma; Head and Neck Neoplasms; Low-grade Glioma; Lung Neoplasms; Meningioma	Details
MNPR-101-Lu177	MNPR-101-PCTA-177Lu; MNPR-101-Lu177	Phase 1 Clinical	Monopar Therapeutics Inc	Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms	Details
MNPR-101-Zr	MNPR-101-Zr; MNPR-101-DFO*-89Zr	Phase 1 Clinical	Monopar Therapeutics Inc, Northstar Medical Radioisotopes Llc	Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms	Details
KMHH-03	KMHH-03; KMHH03	Phase 1 Clinical	Beijing Kangming Haihui Biological Technology Co Ltd	Breast Neoplasms	Details